Form 8-K - Current report
13 Mai 2024 - 10:10PM
Edgar (US Regulatory)
false 0001055726 0001055726 2024-05-13 2024-05-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 13, 2024
Inovio Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-14888 |
|
33-0969592 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
660 W. Germantown Pike, Suite 110 |
Plymouth Meeting, PA 19462 |
(Address of principal executive offices, including zip code) |
(267) 440-4200
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.001 par value |
|
INO |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 |
Results of Operations and Financial Condition. |
On May 13, 2024, Inovio Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
INOVIO PHARMACEUTICALS, INC. |
|
|
|
|
Date: May 13, 2024 |
|
|
|
By: |
|
/s/ Peter Kies |
|
|
|
|
|
|
Peter Kies |
|
|
|
|
|
|
Chief Financial Officer |
Exhibit 99.1
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
|
BLA submission on track for INO-3107 in second half of 2024; if approved
under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (RRP) |
|
|
|
Planning initiation of confirmatory trial for INO-3107 based on FDA
feedback |
|
|
|
Advancing plans for Phase 3 trial of INO-3112 in combination with
LOQTORZITM (toripalimab-tpzi) as a potential treatment for oropharyngeal squamous cell carcinoma (OPSCC) based on FDA feedback |
|
|
|
Balance sheet strengthened with underwritten offering of common stock and
pre-funded warrants completed in April 2024 |
|
|
|
Cash runway projected into third quarter of 2025 |
PLYMOUTH MEETING, PA May 13, 2024 INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to
help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company
developments.
In the first quarter of 2024, we continued to deliver on our priorities for the year. Of utmost importance, we remain on track to
submit our BLA in the second half of 2024 under the accelerated approval pathway for INO-3107 as a treatment for RRP and are working to initiate our confirmatory trial as soon as possible based on feedback
from the FDA on the trials design. We are energized by the opportunity to potentially deliver the first FDA-approved therapy for this devastating disease and continue to work expeditiously to be prepared
to serve RRP patients and the physicians caring for them. If approved, INO-3107 would also be the first DNA medicine on the market in the United States, representing a major milestone for our technology
platform, said Dr. Jacqueline Shea, INOVIOs President and Chief Executive Officer. In parallel, we also made progress with our plans to evaluate INO-3112 in combination with the PD-1 inhibitor, LOQTORZI, in a Phase 3 trial, as we believe the combination could address a substantial unmet need in patients with locoregionally advanced, high-risk,
HPV-16/18 positive OPSCC, a type of head and neck cancer commonly known as throat cancer. We believe that we are aligned with the FDA on our proposed Phase 3 trial design, and we now plan to discuss these
plans with European regulators. We look forward to sharing our continued progress throughout the year.
Recent Business Highlights
INO-3107 Recurrent Respiratory Papillomatosis (RRP)
|
|
|
INOVIO remains on target to submit its BLA seeking accelerated approval for
INO-3107 in the second half of 2024. INOVIO is preparing trial sites for recruitment based on recent feedback from the FDA that they had no additional comments on INOVIOs proposed design for the
confirmatory trial. The trial is being strategically designed to focus on evaluating clinical benefit in reducing surgical intervention to control RRP disease for the majority of RRP patients. Repeat surgical interventions is the current standard of
care for RRP. INOVIOs market research to date with patients and healthcare professionals indicates that a reduction of even one surgery matters, because every surgery poses a significant risk of causing permanent damage to the vocal cords.
|
|
|
|
The proposed confirmatory trial will be randomized and placebo-controlled, involving approximately 100 patients
with a history of ≥2 surgeries per year, with a treatment option for the placebo arm at trial end. This trial design is intended to target a broader spectrum of RRP disease than other candidates currently in development. If INO-3107 receives full approval from the FDA, INOVIO believes the design of the confirmatory trial could also support expansion into global markets based on feedback received to date from European regulators.
|
|
|
|
Immunological data highlighting INO-3107s mechanism of action are
expected to be submitted to peer-reviewed publications and key conferences in the second half of 2024. |
|
|
|
INOVIO continues preparations to be ready to launch commercially in 2025, should
INO-3107 be approved. Efforts are focused on building the infrastructure needed to deliver the product to patients as quickly and easily as possible, from distribution and supply efforts to payer and
healthcare provider support. INOVIO believes that INO-3107, if approved, has the potential to be the preferred treatment of choice for all patients with RRP, as well as healthcare professionals and payers
based on results from completed clinical trials and the competitive strengths of the DNA medicine platform: |
|
|
|
Reduction in surgeries: 81.3% (26/32) of patients had a decrease in surgical interventions in the year
after INO-3107 administration compared to the year prior to treatment, including 28.1% (9/32) that required no surgical interventions during or after the dosing window. INOVIOs Phase 1/2 trial was
designed to show the potential of INO-3107 to reduce surgical intervention in the year following the first dose compared to the year prior. Relative to other Phase 1/2 clinical trials, INOVIOs protocol
required that all surgeries conducted during the dosing window (a 54-day period during which four doses were administered) be counted in the overall results. The protocol for INOVIOs trial also did not
include prescribed laryngoscopy and surgery at weeks 6 and 12 to maintain minimal residual disease during the treatment window. INOVIO believes that these contrasts with other clinical trial designs are important and could offer competitive
advantages for INO-3107 should it be approved. |
|
|
|
Mechanism of action: INO-3107 generated antigen specific T cells
with lytic potential targeting both HPV-6 and HPV-11. |
|
|
|
Immunology: Administration of INO-3107 induced active immune
responses in the airway tissues of those patients who showed clinical response, including the production of cytokines and chemokines, known to be critical mediators of inflammatory responses, and increased activity of dendritic cells, macrophages
and T cells. Additional analysis of T cell genes in airway tissues revealed an increase in CD4 and CD8 T cell gene signatures after treatment with INO-3107. |
|
|
|
Benefits of DNA plasmids plus electroporation: INOVIOs proprietary CELLECTRA® devices are designed to optimally deliver DNA medicines within the bodys cells without requiring chemical adjuvants or lipid nanoparticles, and without the risk of pre-existing or anti-vector responses historically seen with viral vector platforms. In late-stage clinical trials involving approximately 5,600 doses administered to approximately 1,600 patients, intramuscular
delivery has been well tolerated by patients and observed to be easy to use by healthcare providers. Based on historical data from other programs involving redosing, INOVIO believes it will be able to effectively
re-dose INO-3107 if required to maintain or enhance immune responses. |
INO-3112 Oropharyngeal Squamous Cell Carcinoma (OPSCC)
|
|
|
The FDA provided feedback on the proposed Phase 3 trial design to evaluate the combination of INO-3112 and LOQTORZI as a potential treatment for patients with locoregionally advanced, high-risk, HPV-16/-18 positive throat cancer.
|
|
|
|
INOVIO will discuss the proposed trial design with European regulatory authorities, as INOVIO plans to conduct
the trial in both Europe and North America. |
|
|
|
The combination of INO-3112 with LOQTORZI has the potential to address a
substantial unmet need in patients with HPV-16 and -18 related high-risk throat cancer. The proposed multi-center Phase 3 trial will investigate whether LOQTORZI can
help boost the tumor-infiltrating abilities of the antigen-specific T cells generated by INO-3112. |
|
|
|
INO-3112 is a DNA medicine candidate containing a DNA plasmid encoding HPV-16/-18 E6 and E7 antigens combined with another DNA plasmid encoding IL-12 as an immune activator. |
|
|
|
LOQTORZI is an FDA-approved PD-1
inhibitor approved for the treatment of recurrent locally advanced/metastatic nasopharyngeal carcinoma. |
General Corporate
|
|
|
Strengthened balance sheet with an offering of common stock and
pre-funded warrants in April 2024; net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses, were approximately $33.2 million. |
First Quarter 2024 Financial Results
|
|
|
Cash, Cash Equivalents and Short-term Investments: As of March 31, 2024, cash, cash equivalents and
short-term investments were $105.6 million compared to $145.3 million as of December 31, 2023. |
|
|
|
Research and Development (R&D) Expenses: R&D expenses for the three months ended March 31,
2024, were $20.9 million compared to $30.2 million for the same period in 2023. The decrease in R&D expenses was primarily the result of lower drug manufacturing costs related to INO-4800 and
other COVID-19 studies that were discontinued, and lower employee and consultant compensation, including non-cash stock-based compensation, among other variances.
|
|
|
|
General and Administrative (G&A) Expenses: G&A expenses were $10.6 million for the three
months ended March 31, 2024 compared to $13.9 million for the same period in 2023. The decrease in G&A expenses was primarily related to a decrease in employee compensation, including non-cash
employee and consultant stock-based compensation, and a decrease in legal expenses, among other variances. |
|
|
|
Total Operating Expenses: Total operating expenses were $31.5 million for the three months ended
March 31, 2024, compared to $44.1 million for the same period in 2023. |
|
|
|
Reverse Stock Split: INOVIO effected a reverse stock split of its outstanding shares of common stock on
January 24, 2024, as a result of which every twelve shares of its common stock issued and outstanding were combined into one share of common stock. Any fractional post-split shares as a result of the reverse split were eliminated and redeemed
in cash. Outstanding share amounts and per share amounts included in this press release have been restated to reflect the reverse stock split on a retroactive basis for all periods presented. |
|
|
|
Net Loss: INOVIOs net loss for the three months ended March 31, 2024 was $30.5 million, or
$1.31 per basic and diluted share, compared to net loss of $40.6 million, or $1.89 per basic and diluted share, for the three months ended March 31, 2023. |
|
|
|
Shares Outstanding: As of March 31, 2024, INOVIO had 23.4 million common shares outstanding and
25.1 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding options, restricted stock units and convertible preferred stock.
|
INOVIOs balance sheet and statement of operations are provided below. Additional information is included in INOVIOs
quarterly report on Form 10-Q for the quarter ended March 31, 2024, which can be accessed at: http://ir.inovio.com/financials/default.aspx.
Cash Guidance
INOVIO estimates its cash runway,
including the net proceeds of the April 2024 underwritten registered direct offering, to extend into the third quarter of 2025. This projection includes an operational net cash burn estimate of approximately $30 million for the second quarter
of 2024. These cash runway projections do not include any further capital-raising activities that INOVIO may undertake.
Conference Call / Webcast
Information
INOVIOs management will host a live conference call and webcast with slides at 4:30 p.m. ET today to discuss INOVIOs financial
results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIOs website at
http://ir.inovio.com/events-and-presentations/default.aspx.
About INOVIOs DNA Medicines Platform
INOVIOs
DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIOs proprietary investigational medical device, CELLECTRA®. INOVIO uses
proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the bodys cells can download to produce specific proteins to target and fight disease. INOVIOs proprietary CELLECTRA® delivery devices are designed to optimally deliver its DNA medicines to the bodys cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector
response historically seen with viral vector platforms.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from
HPV-related diseases, cancer, and infectious diseases. INOVIOs technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.
For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com
Forward-Looking Statements
This press release contains certain forward-looking statements relating to our business, including our plans to develop and commercialize DNA medicines and our
expectations regarding our research and development programs, including the planned initiation and conduct of clinical trials and the availability and timing of data from those trials, the planned submission of a BLA in the second half of 2024,
plans for discussions with regulatory authorities, the planned commercial launch of INO-3107 if regulatory approval is obtained, and expectations with respect to our cash resources through the third quarter of
2025 and expected cash burn for the second quarter of 2024. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in
pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove
safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones
for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions
targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and
whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can
withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or
other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31,
2023, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any
product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking
information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
Inovio Pharmaceuticals, Inc.
CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
March 31, 2024 |
|
|
December 31, 2023 |
|
|
|
(Unaudited) |
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
19,601,829 |
|
|
$ |
14,310,862 |
|
Short-term investments |
|
|
86,013,044 |
|
|
|
130,982,913 |
|
Accounts receivable from affiliated entities |
|
|
2,551,082 |
|
|
|
2,405,228 |
|
Prepaid expenses and other current assets |
|
|
3,517,081 |
|
|
|
5,393,665 |
|
Prepaid expenses and other current assets from affiliated entities |
|
|
|
|
|
|
20,432 |
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
111,683,036 |
|
|
|
153,113,100 |
|
Fixed assets, net |
|
|
5,015,067 |
|
|
|
4,960,986 |
|
Investment in affiliated entity |
|
|
2,654,269 |
|
|
|
2,780,287 |
|
Operating lease
right-of-use assets |
|
|
9,156,478 |
|
|
|
9,491,735 |
|
Other assets |
|
|
605,315 |
|
|
|
605,315 |
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
129,114,165 |
|
|
$ |
170,951,423 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses |
|
$ |
16,675,922 |
|
|
$ |
19,847,744 |
|
Accounts payable and accrued expenses due to affiliated entity |
|
|
1,525,079 |
|
|
|
1,070,519 |
|
Accrued clinical trial expenses |
|
|
3,022,486 |
|
|
|
2,365,382 |
|
Operating lease liability |
|
|
2,155,540 |
|
|
|
2,406,522 |
|
Grant funding liability |
|
|
|
|
|
|
87,489 |
|
Grant funding liability from affiliated entity |
|
|
21,918 |
|
|
|
21,918 |
|
Convertible senior notes |
|
|
|
|
|
|
16,770,654 |
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
23,400,945 |
|
|
|
42,570,228 |
|
Operating lease liability, net of current portion |
|
|
11,271,257 |
|
|
|
11,032,066 |
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
|
34,672,202 |
|
|
|
53,602,294 |
|
|
|
|
|
|
|
|
|
|
Stockholders equity: |
|
|
|
|
|
|
|
|
Preferred stock |
|
|
|
|
|
|
|
|
Common stock |
|
|
23,370 |
|
|
|
22,792 |
|
Additional paid-in capital |
|
|
1,748,529,814 |
|
|
|
1,740,954,074 |
|
Accumulated deficit |
|
|
(1,653,435,007 |
) |
|
|
(1,622,965,136 |
) |
Accumulated other comprehensive loss |
|
|
(676,214 |
) |
|
|
(662,601 |
) |
|
|
|
|
|
|
|
|
|
Total Inovio Pharmaceuticals, Inc. stockholders equity |
|
|
94,441,963 |
|
|
|
117,349,129 |
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity |
|
$ |
129,114,165 |
|
|
$ |
170,951,423 |
|
|
|
|
|
|
|
|
|
|
Inovio Pharmaceuticals, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2024 |
|
|
2023 |
|
Revenue from collaborative arrangements and other contracts |
|
$ |
|
|
|
$ |
114,943 |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Research and development |
|
|
20,913,790 |
|
|
|
30,176,511 |
|
General and administrative |
|
|
10,571,179 |
|
|
|
13,890,610 |
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
31,484,969 |
|
|
|
44,067,121 |
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(31,484,969 |
) |
|
|
(43,952,178 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
Interest income |
|
|
1,500,290 |
|
|
|
2,207,171 |
|
Interest expense |
|
|
(177,833 |
) |
|
|
(313,488 |
) |
(Loss) gain on investment in affiliated entity |
|
|
(126,018 |
) |
|
|
616,639 |
|
Net unrealized gain on
available-for-sale equity securities |
|
|
500,877 |
|
|
|
3,218,215 |
|
Other expense, net |
|
|
(682,218 |
) |
|
|
(2,425,676 |
) |
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(30,469,871 |
) |
|
$ |
(40,649,317 |
) |
|
|
|
|
|
|
|
|
|
Net loss per share |
|
|
|
|
|
|
|
|
Basic and diluted (1) |
|
$ |
(1.31 |
) |
|
$ |
(1.89 |
) |
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding |
|
|
|
|
|
|
|
|
Basic and diluted (1) |
|
|
23,291,512 |
|
|
|
21,536,476 |
|
|
|
|
|
|
|
|
|
|
(1) |
Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented. |
v3.24.1.1.u2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
Von Jun 2023 bis Jun 2024